German Court revokes GlaxoSmithKline Viani/Advair patent; Company identifies new malaria leads
UK drugs giant GlaxoSmithKline yesterday confirmed that the Federal Patents Court in Munich, Germany, had revoked a patent on its top-selling asthma and chronic obstructive pulmonary disease (COPD) drug Advair/Seratide (salmeterol and fluticasone), which uses the trade name Viani in Germany.
The news saw the company's shares dip 0.7% to £11.69 in morning trading yesterday, closing the day down 1% at £11.66, after having been the only blue chip stock to advance the day earlier in a falling London market. Coincidentally, that upward activity was fueled by a report from MF Global's analyst Justin Smith, who argued that investors have over-reacted to threats of generic competition for Advair, which last year generated sales of $7.8 billion for GSK, or some 18% of group turnover.
Advair sales will carry on growing, says analyst
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze